Contract Award

15 April 2025

Physiomics plc

("Physiomics" or the "Company")

Physiomics Awarded New Contract by Numab Therapeutics

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract with its long-standing client, Numab Therapeutics AG.

The project will involve the application of modelling and simulation techniques to inform pre-clinical development of a multi-specific antibody designed to activate anti-tumor immune responses for the treatment of cancer. This project is expected to complete within the next two months.

This latest collaboration extends the history of the Company working with Numab Therapeutics in applying Model Informed Drug Development to address complex challenges with mathematical modelling and simulation techniques.

Dr Peter Sargent, CEO of Physiomics, commented:

"This new contract marks another step in our long-term collaboration with Numab Therapeutics, reinforcing our role as a trusted partner to provide specialist modelling support to inform critical stages of drug development. We are delighted to be working once again with the Numab team."

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.